Nicholas Smith

Enhanced Clearance of HIV‐1 Broadly Neutralizing Antibody VRC07‐523‐LS During Viremia: Influences on Trial Design and Analysis Broadly neutralizing antibodies (BNAb) are capable of neutralizing multiple HIV-1 strains through the targeting of conserved epitopes. This study's objective was to quantify the pharmacokinetic (PK) ...

Check out our team's recent publication! This work seeks to further develop antibody-based therapies for prevention and treatment of HIV, which could eventually be dosed once a year!

Pharmacodynamic individualization of phage therapy against a KPC-5-producing Pseudomonas aeruginosa AbstractBackground. There is a resurgence of interest in bacteriophage (phage) therapy as antimicrobials, resulting from growing antimicrobial resistance t

Can animal sparing models help individualize phage therapy by better mimicking the human concentrations of phages in the body?

doi.org/10.1093/jaca...

Join us for the International Society of Anti-infective Pharmacology's 2025 Annual Meeting in Vienna!

This year's schedule includes an amazing array of incredible research looking the pharmacology of novel anti-infectives and how we might better use use existing ones!

Meeting is April 10, 2025!

Whole-body Bacteriophage Distribution Characterized by a Physiologically based Pharmacokinetic Model https://www.biorxiv.org/content/10.1101/2025.02.06.636931v1